Martin H. Strauss

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

When Real-World Evidence Meets the Randomized Record: Angiotensin Receptor Blockers, ACE Inhibitors, and the Limits of Inference.

When Real-World Evidence Meets the Randomized Record: Angiotensin Receptor Blockers, ACE Inhibitors, and the Limits of Inference.

Journal: Mayo Clinic proceedings

Published: July 16, 2026

Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular and non-cardiovascular outcomes in patients at high/very-high cardiovascular risk without heart failure: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials †.

Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular and non-cardiovascular outcomes in patients at high/very-high cardiovascular risk without heart failure: a systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials †.

Journal: European heart journal open

Published: December 29, 2025

Real-World Evidence for Causal Inference-Are We Ready?

Real-World Evidence for Causal Inference-Are We Ready?

Journal: Mayo Clinic proceedings

Published: September 02, 2023

ACE inhibitors and the risk of lung cancer-is there causality?

ACE inhibitors and the risk of lung cancer-is there causality?

Journal: British journal of cancer

Published: April 01, 2023

ACEI and ARB - Each Unique RAAS Inhibitors: The Importance of Impact on Inflammation.

ACEI and ARB - Each Unique RAAS Inhibitors: The Importance of Impact on Inflammation.

Journal: Mayo Clinic proceedings

Published: October 23, 2022

The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases.

The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases.

Journal: Cardiovascular drugs and therapy

Published: August 22, 2021

RAAS Inhibitors and Risk of Covid-19.

RAAS Inhibitors and Risk of Covid-19.

Journal: The New England journal of medicine

Published: October 27, 2020

Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention.

Comparison between angiotensin-converting enzyme inhibitor and angiotensin receptor blocker after percutaneous coronary intervention.

Journal: International journal of cardiology

Published: May 03, 2019

Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.

Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.

Journal: Systematic reviews

Published: August 14, 2017

The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus.

The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus.

Journal: Canadian journal of diabetes

Published: August 05, 2017

Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox.

Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox.

Journal: Circulation

Published: June 01, 2017

Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial.

Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial.

Journal: The New England journal of medicine

Published: September 23, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026